Groupe Athena, Inc. year-end financial release is already set in order to provide the public with monetary reports of the company’s fiscal year dated until 30th of June, 2014.
According to the news, Groupe Athena, Inc. is making a progress, particularly in terms of Atorvastatin or generic Lipitor license, which is being sold in the United Kingdom. The license of the product is initially meant for marketing 10 and 20 mg Atorvastatin. UK National Health Service supported this for reports indicated that savings of $1 million GBP daily on the product has been accounted since the patent expiration of Lipitor. Relatively, the Groupe Athena, Inc. is already performing a market research to push through licensing other medications, which include Atenolol for blood pressure.
With the figures on hand, it is expected that at the end of the decade, Groupe Athena, Inc. year-end financial release will mark its double digit growth after 10 years. There is no reservation about this for the company is aggressively expanding its presence in the pharmaceutical industry of India through utilizing its own research and marketing facility. Other than that, GATA was declared to be a part of Groupe Athena, Inc.’s success, specifically in getting the products approved by the USA’s FDA.